Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Inventory (2018 - 2026)

Catalyst Pharmaceuticals filings provide 9 years of Inventory readings, the most recent being $34.9 million for Q1 2026.

  • On a quarterly basis, Inventory rose 76.61% to $34.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $34.9 million, a 76.61% increase, with the full-year FY2025 number at $37.2 million, up 90.19% from a year prior.
  • Inventory hit $34.9 million in Q1 2026 for Catalyst Pharmaceuticals, down from $37.2 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $37.2 million in Q4 2025 to a low of $6.8 million in Q4 2022.
  • Median Inventory over the past 5 years was $18.0 million (2024), compared with a mean of $17.1 million.
  • Biggest five-year swings in Inventory: dropped 13.53% in 2022 and later skyrocketed 129.89% in 2023.
  • Catalyst Pharmaceuticals' Inventory stood at $6.8 million in 2022, then soared by 129.89% to $15.6 million in 2023, then grew by 24.91% to $19.5 million in 2024, then surged by 90.19% to $37.2 million in 2025, then dropped by 6.02% to $34.9 million in 2026.
  • The last three reported values for Inventory were $34.9 million (Q1 2026), $37.2 million (Q4 2025), and $28.0 million (Q3 2025) per Business Quant data.